305 related articles for article (PubMed ID: 35138150)
1. Impact of Empirical Antibiotic Therapy on Outcomes of Outpatient Urinary Tract Infection Due to Nonsusceptible
Dunne MW; Puttagunta S; Aronin SI; Brossette S; Murray J; Gupta V
Microbiol Spectr; 2022 Feb; 10(1):e0235921. PubMed ID: 35138150
[TBL] [Abstract][Full Text] [Related]
2. Interaction between Antibiotic Resistance, Resistance Genes, and Treatment Response for Urinary Tract Infections in Primary Care.
Ho HJ; Tan MX; Chen MI; Tan TY; Koo SH; Koong AYL; Ng LP; Hu PL; Tan KT; Moey PKS; Koh EYL; Wong CS; Lye DC; Tan NC
J Clin Microbiol; 2019 Sep; 57(9):. PubMed ID: 31243084
[TBL] [Abstract][Full Text] [Related]
3. Emergency Department Urinary Tract Infections Caused by Extended-Spectrum β-Lactamase-Producing Enterobacteriaceae: Many Patients Have No Identifiable Risk Factor and Discordant Empiric Therapy Is Common.
Frazee BW; Trivedi T; Montgomery M; Petrovic DF; Yamaji R; Riley L
Ann Emerg Med; 2018 Oct; 72(4):449-456. PubMed ID: 29980462
[TBL] [Abstract][Full Text] [Related]
4. Sulopenem: An Intravenous and Oral Penem for the Treatment of Urinary Tract Infections Due to Multidrug-Resistant Bacteria.
Zhanel GG; Pozdirca M; Golden AR; Lawrence CK; Zelenitsky S; Berry L; Schweizer F; Bay D; Adam H; Zhanel MA; Lagacé-Wiens P; Walkty A; Irfan N; Naber K; Lynch JP; Karlowsky JA
Drugs; 2022 Apr; 82(5):533-557. PubMed ID: 35294769
[TBL] [Abstract][Full Text] [Related]
5. Effect of outpatient antibiotics for urinary tract infections on antimicrobial resistance among commensal Enterobacteriaceae: a multinational prospective cohort study.
Stewardson AJ; Vervoort J; Adriaenssens N; Coenen S; Godycki-Cwirko M; Kowalczyk A; Huttner BD; Lammens C; Malhotra-Kumar S; Goossens H; Harbarth S; ;
Clin Microbiol Infect; 2018 Sep; 24(9):972-979. PubMed ID: 29331548
[TBL] [Abstract][Full Text] [Related]
6. Comparison of fosfomycin to ertapenem for outpatient or step-down therapy of extended-spectrum β-lactamase urinary tract infections.
Veve MP; Wagner JL; Kenney RM; Grunwald JL; Davis SL
Int J Antimicrob Agents; 2016 Jul; 48(1):56-60. PubMed ID: 27234673
[TBL] [Abstract][Full Text] [Related]
7. A multicenter analysis of trends in resistance in urinary Enterobacterales isolates from ambulatory patients in the United States: 2011-2020.
Dunne MW; Aronin SI; Yu KC; Watts JA; Gupta V
BMC Infect Dis; 2022 Feb; 22(1):194. PubMed ID: 35227203
[TBL] [Abstract][Full Text] [Related]
8. The role of extended-spectrum cephalosporin-resistance in recurrent community-onset Enterobacteriaceae urinary tract infections: a retrospective cohort study.
Anesi JA; Lautenbach E; Nachamkin I; Garrigan C; Bilker WB; Omorogbe J; Dankwa L; Wheeler M; Tolomeo P; Han JH;
BMC Infect Dis; 2019 Feb; 19(1):163. PubMed ID: 30764770
[TBL] [Abstract][Full Text] [Related]
9. Retrospective assessment of antimicrobial stewardship initiative in outpatient use of ertapenem for uncomplicated extended spectrum beta lactamase Enterobacteriaceae urinary tract infections.
Wong CP; Delate T; Hudson E; Nguyen JK; Yang SJ; Abraham M
BMC Infect Dis; 2021 Aug; 21(1):823. PubMed ID: 34399680
[TBL] [Abstract][Full Text] [Related]
10. Oral β-Lactam Antibiotics vs Fluoroquinolones or Trimethoprim-Sulfamethoxazole for Definitive Treatment of Enterobacterales Bacteremia From a Urine Source.
Sutton JD; Stevens VW; Chang NN; Khader K; Timbrook TT; Spivak ES
JAMA Netw Open; 2020 Oct; 3(10):e2020166. PubMed ID: 33030555
[TBL] [Abstract][Full Text] [Related]
11. An update on the management of urinary tract infections in the era of antimicrobial resistance.
Bader MS; Loeb M; Brooks AA
Postgrad Med; 2017 Mar; 129(2):242-258. PubMed ID: 27712137
[TBL] [Abstract][Full Text] [Related]
12. Treatment of urinary tract infections among febrile young children with daily intravenous antibiotic therapy at a day treatment center.
Gauthier M; Chevalier I; Sterescu A; Bergeron S; Brunet S; Taddeo D
Pediatrics; 2004 Oct; 114(4):e469-76. PubMed ID: 15466073
[TBL] [Abstract][Full Text] [Related]
13. Temporal trends and risks factors for antimicrobial resistant Enterobacteriaceae urinary isolates from outpatients in Guadeloupe.
Guyomard-Rabenirina S; Malespine J; Ducat C; Sadikalay S; Falord M; Harrois D; Richard V; Dozois C; ; Breurec S; Talarmin A
BMC Microbiol; 2016 Jun; 16(1):121. PubMed ID: 27342199
[TBL] [Abstract][Full Text] [Related]
14. Predicting Antibiotic Resistance in Urinary Tract Infection Patients with Prior Urine Cultures.
Dickstein Y; Geffen Y; Andreassen S; Leibovici L; Paul M
Antimicrob Agents Chemother; 2016 Aug; 60(8):4717-21. PubMed ID: 27216064
[TBL] [Abstract][Full Text] [Related]
15. Oral treatment options for patients with urinary tract infections caused by extended spectrum βeta-lactamase (ESBL) producing Enterobacteriaceae.
Raja NS
J Infect Public Health; 2019; 12(6):843-846. PubMed ID: 31176606
[TBL] [Abstract][Full Text] [Related]
16. Poor clinical outcomes associated with community-onset urinary tract infections due to extended-spectrum cephalosporin-resistant Enterobacteriaceae.
Anesi JA; Lautenbach E; Nachamkin I; Garrigan C; Bilker WB; Omorogbe J; Dankwa L; Wheeler MK; Tolomeo P; Han JH;
Infect Control Hosp Epidemiol; 2018 Dec; 39(12):1431-1435. PubMed ID: 30375298
[TBL] [Abstract][Full Text] [Related]
17. Clinical evaluation of guidelines and therapeutic approaches in multi drug-resistant urinary tract infections.
Concia E; Bragantini D; Mazzaferri F
J Chemother; 2017 Dec; 29(sup1):19-28. PubMed ID: 29271735
[TBL] [Abstract][Full Text] [Related]
18. Antibiotic treatment failure of uncomplicated urinary tract infections in primary care.
Koh SWC; Ng TSM; Loh VWK; Goh JC; Low SH; Tan WZ; Wong HC; Durai P; Sun LJ; Young D; Tambyah PA
Antimicrob Resist Infect Control; 2023 Aug; 12(1):73. PubMed ID: 37528415
[TBL] [Abstract][Full Text] [Related]
19. Risk analysis of antimicrobial resistance in outpatient urinary tract infections of young healthy adults.
Brosh-Nissimov T; Navon-Venezia S; Keller N; Amit S
J Antimicrob Chemother; 2019 Feb; 74(2):499-502. PubMed ID: 30357329
[TBL] [Abstract][Full Text] [Related]
20. Empirical treatment of urinary tract infections: how rational are our guidelines?
O'Grady MC; Barry L; Corcoran GD; Hooton C; Sleator RD; Lucey B
J Antimicrob Chemother; 2019 Jan; 74(1):214-217. PubMed ID: 30295780
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
